Mérieux Equity Partners

What Mérieux Equity Partners does

Mérieux Equity Partners is a healthcare-specialized European private equity and venture capital firm founded in 2009 and headquartered in Lyon, France, with a second office in Paris. The firm invests exclusively across the Healthcare and Nutrition sectors through two dedicated platforms: an Innovation platform (Mérieux Innovation 2, targeting €3–15m tickets in seed-to-Series B companies with minority ownership, focused on diagnostics, therapeutics, biodrugs, medtech and pharma services) and a Buyout platform (Mérieux Participations 4, closed at €568m above its €500m target, deploying €20–80m majority or minority tickets in profitable, fast-growing healthcare companies). Across both vehicles the firm manages more than €1.6bn in third-party capital and has completed 60+ investments since inception.

The firm benefits from a longstanding affiliation with Institut Mérieux (founded 1897), parent of bioMérieux, granting access to scientific, commercial and operational networks across European healthcare. It is registered with the French Autorité des Marchés Financiers (AMF) under GP-18000009 since June 2018, is a UN PRI signatory, holds the Tibi Label (2024), and is a member of the European Healthcare Private Equity Association. The investment team of 18 professionals includes PhDs in pharmacy and pharmacology, former operating executives at bioMérieux, Mérieux NutriSciences, and Institut Mérieux, plus alumni of specialist healthcare PE firms such as Keensight Capital, ArchiMed, eureKARE, and Cathay Capital.

Revenue is generated through a standard private equity model: recurring management fees on committed/invested capital across its fund vehicles, supplemented by performance-based carried interest on successful exits. Customers effectively split between (i) institutional LPs sourcing diversified European healthcare mandates and (ii) portfolio companies receiving capital, board-level support, and sector network access. Notable recent transactions include acquisitions of Curea Medical, InnoSyn, Labquality, Piercan and a minority stake in Health in Code; venture investments in Ona Therapeutics, deepull, SeqOne Genomics and Broken String Biosciences; and exits including Plantex (to Nactarome), GTP Bioways (to Olon), Mabtech (to EQT) and Swixx Biopharma (to SK Capital and Bain Capital Life Sciences).

Name

Mérieux Equity Partners

Legal name

MERIEUX EQUITY PARTNERS SAS

Website

https://merieux-partners.com

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

11–50 employees

Short description

Mérieux Equity Partners is a Lyon-based European private equity firm founded in 2009 that invests exclusively in Healthcare and Nutrition companies via two platforms: Innovation (seed to Series B, €3–15m) and Buyout (MP4 at €568m, €20–80m), managing over €1.6bn in AUM.

Ownership category

akta.pro rank

Product category

Healthcare Private Equity & Venture Capital

NAICS

Funds, Trusts, and Other Financial Vehicles (525), Other Financial Vehicles (525990)

SIC

Investment Advice (6282)

akta.pro primary industry

Corporate Strategic Partnership & Ecosystem Investment Arms (FSANAHAF)

akta.pro secondary industry

Venture Debt Providers (FSANAAAL)

Keywords

• Healthcare private equity
• Venture capital investment
• Buyout investment platform
• Biotech investment management
• Healthcare growth capital

Headquarters

HQ city

Lyon

HQ country

France

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

1. Management Fees: The firm charges management fees on committed capital from their funds (Mérieux Innovation 2, MP4, and other vehicles). They manage third-party capital and are AMF-registered.
2. Carried Interest: Performance-based carried interest from successful exits of portfolio companies across their investment funds.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

Mérieux Equity Partners is a healthcare-specialized private equity investment firm that manages third-party capital through two dedicated platforms: an Innovation platform (seed to Series B, €3m-€15m tickets, minority stakes) supporting innovative medical solutions, and a Buyout platform (€20m-€80m tickets, majority or minority stakes) investing in profitable, fast-growing healthcare companies. The firm manages €1.6bn+ in assets under management across funds including Mérieux Participations 4 (MP4, closed at €568m) and Mérieux Innovation 2.

Product overview

Mérieux Equity Partners is a healthcare-specialized investment firm that does not offer a product in the traditional sense. Rather, the company operates two investment platforms: Innovation (venture capital supporting innovative medical solutions from seed to series B) and Buyout (growth and buyout investments in profitable healthcare companies). The firm manages multiple funds including Mérieux Participations 4 (MP4), Mérieux Innovation 2, and others, and has a portfolio of healthcare investments across diagnostics, biotech, medtech, animal health, and pharma services sectors.

Differentiator

Problem solved

Functional benefit

Products and services

• Innovation Platform (Venture Capital)
• Buyout Platform (Growth Buyout)
• Mérieux Participations 4 (MP4) Fund
• Mérieux Innovation 2 (MI2) Fund
• Mérieux Participations 3 (MP3) Fund

Quantifiable outcome

• 60+ investments completed since 2009
• +2 more outcomes

Named customers10 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators6 records

Recent moves10 records

Expansion highlights6 records

Direct peers

• Keensight Capital: Paris-based European growth PE firm exclusively focused on technology and healthcare. Direct competitor for healthcare mid-market buyout deals across Europe and overlapping LP base with Mérieux.
• ArchiMed: France-headquartered PE firm dedicated to healthcare with growth and buyout strategies across Europe. Closest direct competitor given similar AUM scale, healthcare-only mandate, and Buyout-led model.
• GHO Capital Partners: London-based PE firm exclusively focused on European healthcare, operating across growth buyouts. Directly comparable strategy, mandate, and target company profiles to Mérieux's Buyout platform.
• Andera Partners: French PE/VC firm with dedicated Life Sciences and Healthcare strategies covering venture through growth. Comparable to Mérieux's dual Innovation/Buyout platform with overlapping French and European healthcare deal sourcing.
• Sofinnova Partners: Paris-based leading European life sciences VC investing across biopharma, medtech, and digital health from early-stage to crossover. Closest direct competitor to Mérieux's Innovation platform.

Broad incumbents

• EQT Life Sciences: European healthcare/life-sciences growth investor within broader EQT platform. Larger AUM and global reach make EQT a broader incumbent overlapping with Mérieux on growth-stage healthcare deals.
• Bain Capital Life Sciences: Global healthcare-dedicated PE/VC within Bain Capital. Recently acquired Swixx BioPharma from Mérieux. Larger AUM and global mandate make it a broad incumbent competing for upper-end deals.
• IK Partners: European mid-market PE firm with healthcare among key verticals. Co-exited Mabtech with Mérieux. Comparable European mid-market focus with broader sector mandate.
• Novo Holdings: Danish healthcare-dedicated investment firm with venture, growth, and buyout strategies globally. Comparable healthcare-only focus with substantially larger AUM and broader geographic reach than Mérieux.

Regional players

• HealthTech investor (CapHorn): French growth-stage investor with strong healthcare and tech focus. Overlaps with Mérieux Innovation on French Series A/B healthcare deals; smaller scale and narrower mandate.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/merieux-equity-partners

Compliance7 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles16 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A6 records

Investments60 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mérieux Equity Partners